The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Earlier, Yahoo Finance discussed this stock as it revealed Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024.
Roivant Sciences Ltd is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $10.57 and fluctuated between $10.61 as its day high and $10.31 as its day low. The current market capitalization of Roivant Sciences Ltd is $8.50B. A total of 7.14 million shares were traded on the day, compared to an average of 5.32M shares.
In the most recent transaction, Ramaswamy Vivek sold 3,000,000 shares of ROIV for 11.05 per share on Jan 02. After the transaction, the 10% Owner now owns 51,929,426 company shares. In a previous transaction on Oct 05, Venker Eric sold 153,027 shares at 10.11 per share. ROIV shares that Chief Operating Officer owns now total 595,397.
Among the insiders who sold shares, Venker Eric disposed of 606,221 shares on Oct 03 at a per-share price of $10.25. This resulted in the Chief Operating Officer holding 595,397 shares of ROIV after the transaction. In another insider transaction, Roivant Sciences Ltd. bought 1,526,316 shares at $38.00 per share on Oct 02. Company shares held by the Director now total 79,805,331.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for ROIV in the last 3 months, the mean price target is $16.20 with high estimates of $23.00 and low estimates of $12.00. In terms of 52-week highs and lows, ROIV has a high of $13.24 and a low of $6.59.
As of this writing, ROIV has an earnings estimate of $Roivant Sciences Ltd. per share for the current quarter. EPS was calculated based on a consensus of RiskOn International, Inc. estimates, with a high estimate of $Retail Opportunity Investments per share and a lower estimate of $RiverNorth Opportunities Fund,.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ROIV’s latest balance sheet shows that the firm has $2.06B in Cash & Short Term Investments as of fiscal 2022. There were $283.89M in debt and $184.37M in liabilities at the time. Its Book Value Per Share was $1.18, while its Total Shareholder’s Equity was $2.06B.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ROIV is Buy with a score of 4.83.